These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 6469927)

  • 21. Validation of four definitions of melancholia by the dexamethasone suppression test.
    Davidson J; Lipper S; Zung WW; Strickland R; Krishnan R; Mahorney S
    Am J Psychiatry; 1984 Oct; 141(10):1220-3. PubMed ID: 6486256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexamethasone suppression test in first-episode schizophrenia.
    Cesková E; Kaspárek T; Zourková A; Prikryl R
    Neuro Endocrinol Lett; 2006 Aug; 27(4):433-7. PubMed ID: 16892008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between depression and the dexamethasone suppression test following alcohol withdrawal in a psychiatric population.
    Johnson B; Perry JC
    J Clin Psychopharmacol; 1986 Dec; 6(6):343-9. PubMed ID: 3805327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight.
    Perez EL; Blouin J; Blouin A
    J Clin Psychiatry; 1988 Mar; 49(3):94-6. PubMed ID: 3346203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4 p.m. baseline cortisol level as a predictor of DST results in depression.
    Weiler MA; Jobe TH; Nasr SJ; Pandey G; Altman EG
    J Clin Psychiatry; 1986 Feb; 47(2):60-2. PubMed ID: 3944064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment dexamethasone suppression test as a predictor of response to phenelzine.
    Janicak PG; Pandey GN; Sharma R; Boshes R; Bresnahan D; Davis JM
    J Clin Psychiatry; 1987 Dec; 48(12):480-2. PubMed ID: 3693333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cortisol suppression index: a further evaluation.
    Zung WW; Denton WH; Mahorney S
    J Clin Psychiatry; 1984 Oct; 45(10):437-8. PubMed ID: 6480570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dexamethasone suppression test as an adjunct in diagnosing depression.
    Lawson WB; Herrera JM; Costa J
    J Assoc Acad Minor Phys; 1992; 3(1):17-9. PubMed ID: 1576455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utilization of the dexamethasone suppression test.
    Coccaro EF; Prudic J; Rothpearl A; Nurnberg HG
    J Clin Psychiatry; 1984 Sep; 45(9):382-4. PubMed ID: 6469922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression, negative and positive symptoms, and the DST in schizophrenia.
    Minas IH; Jackson HJ; Joshua SD; Burgess PM
    Schizophr Res; 1990; 3(5-6):321-7. PubMed ID: 2282337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of laboratory tests in psychiatric diagnosis: the DST as an example.
    Coryell W
    Psychiatr Dev; 1984; 2(3):139-59. PubMed ID: 6393122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pituitary-adrenal disinhibition as the independent variable in the assessment of behavioral symptoms.
    Reus VI
    Biol Psychiatry; 1982 Mar; 17(3):317-26. PubMed ID: 7082699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical complaints correlate better with depression than do dexamethasone suppression test results.
    Silver H
    J Clin Psychiatry; 1986 Apr; 47(4):179-81. PubMed ID: 3957876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexamethasone suppression test and Axis I diagnoses of inpatients with DSM-III borderline personality disorder.
    Baxter L; Edell W; Gerner R; Fairbanks L; Gwirtsman H
    J Clin Psychiatry; 1984 Apr; 45(4):150-3. PubMed ID: 6715286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The dexamethasone suppression test in schizophrenia and endogenous depression].
    Strzelecka I; Matkowski K; Linka M; Kanarkowski R; Kretowicz W; Chmielewska Z; Rybakowski J
    Psychiatr Pol; 1988; 22(1):1-7. PubMed ID: 3406212
    [No Abstract]   [Full Text] [Related]  

  • 36. The dexamethasone suppression test in patients with mood disorders.
    Rush AJ; Giles DE; Schlesser MA; Orsulak PJ; Parker CR; Weissenburger JE; Crowley GT; Khatami M; Vasavada N
    J Clin Psychiatry; 1996 Oct; 57(10):470-84. PubMed ID: 8909334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression.
    Rush AJ; Giles DE; Schlesser MA; Orsulak PJ; Weissenburger JE; Fulton CL; Fairchild CJ; Roffwarg HP
    Biol Psychiatry; 1997 May; 41(9):915-28. PubMed ID: 9110097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions.
    Stewart JW; Quitkin FM; McGrath PJ; Klein DF
    J Affect Disord; 2005 Jun; 86(2-3):161-7. PubMed ID: 15935235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dexamethasone suppression test in adolescent psychiatric inpatients.
    Targum SD; Capodanno AE
    Am J Psychiatry; 1983 May; 140(5):589-91. PubMed ID: 6846588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in serial dexamethasone suppression tests among unipolar depressive receiving electroconvulsive treatment.
    Albala AA; Greden JF; Tarika J; Carroll BJ
    Biol Psychiatry; 1981 Jun; 16(6):551-60. PubMed ID: 7260217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.